Wells Fargo Maintains Equal-Weight on Conmed, Lowers Price Target to $39

Benzinga Newsdesk www.benzinga.com Neutral 66.4%

Neg 0% Neu 66.4% Pos 0%

Wells Fargo analyst Larry Biegelsen maintains Conmed (NYSE:CNMD) with a Equal-Weight and lowers the price target from $42 to $39.